Unlike genetic mutations, epigenetic modifications are potentially reversible. This characteristic makes them attractive targets for therapeutic intervention. Drugs such as DNA methyltransferase inhibitors (e.g., azacitidine) and histone deacetylase inhibitors (e.g., vorinostat) are already in use, and many more are in development.
